1-8 of 8
Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Philippe Moreau, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Michael E O'Dwyer, MD, Mamta Garg, MD FRCP, FRCPath, Elizabeth A Punnoose, PhD, Muhammad Jalaluddin, PhD, Jia Jia, PhD MBA, Xiaoqing Yang, PhD, Yan Sun, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 142.
https://doi.org/10.1182/blood-2019-126094
Published: 2019
Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard
Journal: Blood
Blood (2019) 134 (Supplement_1): 269.
https://doi.org/10.1182/blood-2019-129431
Published: 2019
Journal Articles

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Cristina Gasparetto, MD, Rakesh Popat, Shaji K. Kumar, MD, Michele Cavo, Javier de la Rubia, MD PhD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, James Maciel, Liang-Tsai Hsiao, Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Jia Jia, PhD MBA, Sudeep Karve, PhD, Esprit Ma, Jacob Devine, MA, Katy Benjamin
Journal: Blood
Blood (2019) 134 (Supplement_1): 3177.
https://doi.org/10.1182/blood-2019-127387
Published: 2019
Journal Articles

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

Slavisa Ninkovic, MBBS FRACP FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Lenny Straszkowski, BSci Hons, Giulia Quattrocchi, Wee-Joo Chng, MBBS, PhD, Louise E Purton, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4376.
https://doi.org/10.1182/blood-2019-128190
Published: 2019
Journal Articles

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Amandeep Kaur, PhD, Katherine M Hannan, PhD, Samina Nazir, MSc, Kylee H Maclachlan, FRACP,FRCPA, Gretchen Poortinga, PhD, Si Ming Man, PhD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Ross D Hannan, PhD, Elizabeth E. Gardiner, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2360.
https://doi.org/10.1182/blood-2019-121713
Published: 2019
Journal Articles

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Francesca Gay, MD, Gábor Mikala, MD PhD, Elizabeth A Punnoose, PhD, Wan-Jen Hong, MD, Anjla Sood, MD, Muhammad Jalaluddin, PhD, Jeremy A. Ross, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1888.
https://doi.org/10.1182/blood-2019-126015
Published: 2019
Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 925.
https://doi.org/10.1182/blood-2019-124407
Published: 2019
Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM
Journal: Blood
Blood (2019) 134 (Supplement_1): 3144.
https://doi.org/10.1182/blood-2019-130084
Published: 2019